208 related articles for article (PubMed ID: 34310849)
1. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
2. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
4. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.
Santos-Laso A; Izquierdo-Sanchez L; Rodrigues PM; Huang BQ; Azkargorta M; Lapitz A; Munoz-Garrido P; Arbelaiz A; Caballero-Camino FJ; Fernández-Barrena MG; Jimenez-Agüero R; Argemi J; Aragon T; Elortza F; Marzioni M; Drenth JPH; LaRusso NF; Bujanda L; Perugorria MJ; Banales JM
Liver Int; 2020 Jul; 40(7):1670-1685. PubMed ID: 32378324
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
8. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
9. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
Ji R; Chen J; Xie Y; Dou X; Qing B; Liu Z; Lu Y; Dang L; Zhu X; Sun Y; Zheng X; Zhang L; Guo D; Chen Y
J Hepatol; 2023 Apr; 78(4):754-769. PubMed ID: 36681161
[TBL] [Abstract][Full Text] [Related]
12. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
13. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
[TBL] [Abstract][Full Text] [Related]
14. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-Martínez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
Caballero-Camino FJ; Rivilla I; Herraez E; Briz O; Santos-Laso A; Izquierdo-Sanchez L; Lee-Law PY; Rodrigues PM; Munoz-Garrido P; Jin S; Peixoto E; Richard S; Gradilone SA; Perugorria MJ; Esteller M; Bujanda L; Marin JJG; Banales JM; Cossío FP
Hepatology; 2021 Jan; 73(1):186-203. PubMed ID: 32145077
[TBL] [Abstract][Full Text] [Related]
16. Protein neddylation and its alterations in human cancers for targeted therapy.
Zhou L; Zhang W; Sun Y; Jia L
Cell Signal; 2018 Apr; 44():92-102. PubMed ID: 29331584
[TBL] [Abstract][Full Text] [Related]
17. UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
Heo MJ; Kang SH; Kim YS; Lee JM; Yu J; Kim HR; Lim H; Kim KM; Jung J; Jeong LS; Moon A; Kim SG
Int J Cancer; 2020 Nov; 147(9):2550-2563. PubMed ID: 32449166
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers.
Yin L; Xue Y; Shang Q; Zhu H; Liu M; Liu Y; Hu Q
Curr Top Med Chem; 2019; 19(12):1059-1069. PubMed ID: 30854973
[TBL] [Abstract][Full Text] [Related]
19. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
20. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
